These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11504670)

  • 1. Pathophysiological effects of aldosterone in cardiovascular tissues.
    Rocha R; Stier CT
    Trends Endocrinol Metab; 2001 Sep; 12(7):308-14. PubMed ID: 11504670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone as a mediator in cardiovascular injury.
    Stier CT; Chander PN; Rocha R
    Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone and end-organ damage.
    Brown NJ
    Curr Opin Nephrol Hypertens; 2005 May; 14(3):235-41. PubMed ID: 15821416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.
    Bravo EL
    Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
    Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salt, aldosterone and hypertension.
    Pimenta E; Gordon RD; Stowasser M
    J Hum Hypertens; 2013 Jan; 27(1):1-6. PubMed ID: 22785050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone and cardiovascular disease.
    Gaddam KK; Pimenta E; Husain S; Calhoun DA
    Curr Probl Cardiol; 2009 Feb; 34(2):51-84. PubMed ID: 19135616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
    Young MJ; Funder JW
    J Hypertens; 2002 Aug; 20(8):1465-8. PubMed ID: 12172301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
    Chrissobolis S
    Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of aldosterone.
    Murin J
    Bratisl Lek Listy; 2005; 106(1):3-19. PubMed ID: 15869008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone, organ damage and dietary salt.
    Catena C; Colussi G; Sechi LA
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):922-8. PubMed ID: 23803228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aldosterone and MR blockade on the brain and the kidney.
    Stier CT; Rocha R; Chander PN
    Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension.
    Ardhanari S; Kannuswamy R; Chaudhary K; Lockette W; Whaley-Connell A
    Adv Chronic Kidney Dis; 2015 May; 22(3):185-95. PubMed ID: 25908467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism.
    Epstein M
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):993-1003. PubMed ID: 26429402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of mineralocorticoid receptor antagonists in cardiovascular disease.
    Ferrario CM; Schiffrin EL
    Circ Res; 2015 Jan; 116(1):206-13. PubMed ID: 25552697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aldosterone receptor blockade in the management of cardiovascular disease.
    Liew D; Krum H
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.